• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA blocks new use for AstraZeneca's Ultomiris

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 06, 2023 at 10:12: AM
via AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is.

article source
 




Top Bottom
Back
Quote